ALNYLAM PHARMACEUTICALS, INC. (ALNY) Earnings
ALNYLAM PHARMACEUTICALS, INC.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Next earnings (estimated)
Around Oct 29, 2026
From past filing pattern
Get notified when ALNY reports →Last reported earnings
Jul 30, 2026
From the latest earnings 8-K
Revenue • FY2025
$3.71B
▲ 65.2%YoY
Diluted EPS • FY2025
$2.33
▲ 206.9%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from ALNY's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $3.71B | $313.75M | $3.04B | $2.33 | $465.38M | 13.5% | +65.2% |
| FY2024 | $2.25B | -$278.16M | $1.94B | $-2.18 | -$42.59M | -7.9% | +23.0% |
| FY2023 | $1.83B | -$440.24M | $1.56B | $-3.52 | $41.95M | -15.4% | +76.2% |
| FY2022 | $1.04B | -$1.13B | $897.24M | $-9.30 | -$613.33M | -75.7% | +22.9% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Jul 30, 2026 | 8-K (2.02) | 0001178670-26-000060EDGAR |
| Apr 30, 2026 | 8-K (2.02) | 0001628280-26-028601EDGAR |
| Feb 12, 2026 | 8-K (2.02) | 0001628280-26-007491EDGAR |
| Jan 12, 2026 | 8-K (2.02) | 0001628280-26-001755EDGAR |
| Oct 30, 2025 | 8-K (2.02) | 0001628280-25-047342EDGAR |
| Jul 31, 2025 | 8-K (2.02) | 0001178670-25-000089EDGAR |
| Jan 13, 2025 | 8-K (2.02) | 0001178670-25-000008EDGAR |
Earnings for companies related to ALNY
Never miss a ALNY filing.
Get an email when ALNY files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Oct 17, 2026Source: SEC EDGAR.